Intellia Therapeutics financial and clinical updates

Intellia Therapeutics has reported its second-quarter 2026 financial results, characterized by widening net losses and declining collaboration revenues. The company reported a net loss of $106.6 million, compared to $101.3 million in the same period the previous year, citing increased investments to prepare its gene therapy pipeline for commercial marketing.

Revenue from collaborations fell to $7.7 million, missing market expectations of approximately $13 million. Despite these financial shifts, the company reported positive clinical developments, specifically noting that its phase III HALO trial for Lonvo-z showed an “87% reduction in mean monthly HAE attacks compared to a placebo.”

Intellia maintains a strong liquidity position, supported by a capital increase in April that provided approximately $195 million in net proceeds. The company expects its rolling BLA to be accepted by the FDA by the end of the year, with a target U.S. launch for Lonvo-z in the first half of 2027. Current cash and marketable securities are expected to provide a runway into at least 2028.